Clinical Audit on the Managment in Assiut University Children Hospital

March 24, 2021 updated by: Patricia reda hanna, Assiut University

Clinical Audit on the Managment of Rheumatic Fever in Assiut University Children Hospital

clinical audit on the Managment of rheumatic fever in assiut university children hospital.

Study Overview

Detailed Description

Acute rheumatic fever,an auto immune response to Group A streptococcus infection of the upper respiratory tract,may result in carditis.when the inflammation leads to permenant damage of the valves the individual has rheumatic heart disease.

Recurrences of rheumatic fever are likely in the absence of preventive measures and may cause further cardiac valve and muscle damage,leading to heart failure,stroke and premature death.bacterial endocarditis is also a complication.

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Assiut, Egypt
        • Egypt

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

5 years to 15 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Clinical audit on the managment of rheumatic fever in assiut university children hospital

Description

Inclusion Criteria:

  • patients with confirmed diagnosis of rheumatic fever based on laboratory investigations.

Exclusion Criteria:

  • No

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
laboratory investigations (ASOt , ESR . CRP)
Time Frame: One year from October 2017 to september 2018
laboratory investigations that measure the inflammation process will be used and the target that the ASOt not increase 1/400
One year from October 2017 to september 2018

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
clinical measures
Time Frame: One year from October 2017 to september 2018
improvement of arthritis if found
One year from October 2017 to september 2018

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2018

Primary Completion (Actual)

March 24, 2020

Study Completion (Actual)

March 24, 2020

Study Registration Dates

First Submitted

August 29, 2017

First Submitted That Met QC Criteria

September 11, 2017

First Posted (Actual)

September 13, 2017

Study Record Updates

Last Update Posted (Actual)

March 26, 2021

Last Update Submitted That Met QC Criteria

March 24, 2021

Last Verified

March 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rheumatic Fever

Clinical Trials on C reactive protein, anti streptolysin o antibody test ,erythrocyte sedimentation rate

3
Subscribe